Whitehawk Therapeutics Inc (WHWK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	7.1M	26.0M	24.4M	15.2M
Cost of Revenue	5.0K	760.0K	54.1M	51.7M	34.0M
Gross Profit	(5.0K)	6.4M	(28.1M)	(27.4M)	(18.8M)
Operating Expenses
R&D Expense	63.5M	91.0M	51.0M	48.9M	32.7M
SG&A Expense	22.6M	29.8M	36.7M	44.5M	40.2M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	(48.4M)	(48.9M)	(28.9M)
Total Operating Expenses	86.1M	120.8M	39.4M	44.5M	43.9M
Cost and Expenses	86.1M	121.5M	93.4M	96.3M	77.9M
Operating Income (EBIT)	(86.1M)	(114.4M)	(67.5M)	(71.9M)	(62.7M)
Non-Operating
Interest Income	6.3M	6.2M	3.9M	6.4M	2.4M
Interest Expense	—	—	154.0K	231.0K	230.0K
Net Interest Income	6.3M	6.2M	3.8M	6.2M	2.2M
Other Non-Op Income/Expense	6.2M	93.8M	3.8M	6.2M	2.2M
Non-Operating Income (excl Interest)	(4.8M)	(93.8M)	(2.6M)	(6.4M)	(3.7M)
EBT (Pre-Tax Income)	(79.8M)	(20.6M)	(63.7M)	(65.8M)	(60.5M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(79.8M)	(20.6M)	(63.7M)	(65.8M)	(60.5M)
Earnings from Cont. Ops	(79.8M)	(20.6M)	(63.7M)	(65.8M)	(60.5M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(79.8M)	(20.6M)	(63.7M)	(65.8M)	(60.5M)
Per Share
Basic EPS	($1.12)	($0.33)	($2.36)	($2.44)	($2.69)
Diluted EPS	($1.12)	($0.33)	($2.36)	($2.44)	($2.69)
Revenue Per Share	$0.00	$0.12	$0.96	$0.90	$0.68
Shares
Basic Shares Outstanding	82.9M	61.9M	27.0M	26.9M	22.5M
Diluted Shares Outstanding	82.9M	61.9M	27.0M	26.9M	22.5M
Profitability Metrics
EBITDA	(81.3M)	(20.5M)	(64.6M)	(65.4M)	(58.8M)
D&A	7.0K	79.0K	193.0K	169.0K	159.0K
EBIT	(81.3M)	(20.6M)	(64.8M)	(65.5M)	(59.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026